Secure CheckoutPersonal information is secured with SSL technology.
Free ShippingFree global shipping
No minimum order.
1. MicroRNAs and Cancer: A Long Story for Short RNAs
Alessandra Drusco and Carlo M. Croce
2. The Enigma of miRNA Regulation in Cancer
Anjan K. Pradhan, Luni Emdad, Swadesh K. Das, Devanand Sarkar and Paul B. Fisher
3. Animal Models to Study microRNA Functions
Arpita S. Pal and Andrea L. Kasinski
4. Cancer Hallmarks and MicroRNAs: The Therapeutic Connection
Katrien Van Roosbroeck and George A. Calin
5. microRNAs in Cancer Susceptibility
Brid M. Ryan
6. Role of the tRNA-Derived Small RNAs in Cancer: New Potential Biomarkers and Target for Therapy
Veronica Balatti, Yuri Pekarsky and Carlo M. Croce
7. MicroRNAs and Epigenetics
Catia Moutinho and Manel Esteller
miRNA and Cancer, Volume 135, the latest volume in the Advances in Cancer Research series, provides invaluable information on the exciting and fast-moving field of cancer research. This volume presents original reviews on research bridging oncology and gene expression, and includes specific chapters on Non-coding RNAs as Biomarkers of Cancer, The Enigma of microRNA Regulation in Cancer, Animal Models to Study microRNA functions, Non-coding RNAs and Cancer, microRNAs in Cancer Susceptibility, ts-RNAs versus microRNAs, microRNAs and AML, and microRNAs and Epigenetics.
- Provides information on cancer research
- Offers outstanding and original reviews on a range of cancer research topics
- Serves as an indispensable reference for researchers and students alike
Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology
- No. of pages:
- © Academic Press 2017
- 2nd September 2017
- Academic Press
- Hardcover ISBN:
- eBook ISBN:
Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA
The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.
Department of Cell and Molecular Pharmacology, Medical University of South Carolina, USA
Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 600 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).
Institute of Molecular Medicine, Virginia Commonwealth University, VA, USA
Professor Carlo Croce is a renowned figure in the field of genetics and cancer. He has received numerous awards and accolades for his work, not least his research into the molecular mechanisms of leukemia which earned him the 2006 Clowes Memorial Award from the American Association for Cancer Research.
Professor, Department of Cancer Biology and Genetics, College of Medicine, Ohio State University